The CTS results suggest significant breast cancer protection in women with preeclampsia who possess the IGF1R rs2016347 TT genotype, specifically in those with age at first birth under 30 and for subsequent development of HR+ breast cancer. The gene discussed is IGF1R; the disease is breast carcinoma.